Co-diagnostics, inc receives ce marking for direct saliva sars-cov-2 test

Salt lake city, june 18, 2021 /prnewswire/ -- co-diagnostics, inc. (nasdaq: codx), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that its logix smart™ sars-cov-2 ds (direct saliva) has obtained regulatory authorization to be sold as an in vitro diagnostic ("ivd") for the diagnosis of covid-19 in markets that accept ce markings, and is now available for purchase from the company's utah-based iso-13485:2016 certified facility. co-diagnostics' logix smart ds test kit is designed to detect the presence of the rdrp and e genes of sars-cov-2 directly from minimally processed human saliva samples while eliminating rna extraction of the samples, a costly and time-consuming process required by most pcr tests.
CODX Ratings Summary
CODX Quant Ranking